Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials

Bone

Volumn 68, Issue , 2014, Pages 115-123

  Zhu, Zhong Ning ^a   Jiang, Yun Fa ^a   Ding, Tao ^b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Fractures; Meta analysis; Pioglitazone; Rosiglitazone; Thiazolidinediones

Indexed keywords

GLIBENCLAMIDE; GLITAZONE DERIVATIVE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FRACTURE; GENETIC HETEROGENEITY; GLUCOSE TOLERANCE TEST; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEX DIFFERENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; BONE; CHEMICALLY INDUCED; DRUG EFFECTS; PATHOLOGY; PATHOPHYSIOLOGY; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; RISK FACTOR;

ADULT; AGED; BONE AND BONES; BONE DENSITY; FEMALE; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 84908564226     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.08.010     Document Type: Article

References (41)

1. Grey A., Bolland M., Fenwick S., Horne A., Gamble G., Drury P.L., et al. The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. Eur J Endocrinol 2014, 170(2):255-262.
2. Sinha B., Ghosal S. Pioglitazone-do we really need it to manage type 2 diabetes?. Diabetes Metab Syndr 2013, 7(1):52-55.
3. Hashim S., Gomes T., Juurlink D., Hellings C., Mamdani M. The rise and fall of the thiazolidinediones: impact of clinical evidence publication and formulary change on the prescription incidence of thiazolidinediones. J Popul Ther Clin Pharmacol 2013, 20(3):e238-e242.
4. Food and Drug Administration FDA drug safety communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines [accessed Nov 25, 2013]. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm376683.htm.
5. Loke Y.K., Singh S., Furberg C.D. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009, 180(1):32-39.
6. Toulis K.A., Goulis D.G., Anastasilakis A.D. Thiazolidinedione use and the risk of fractures. CMAJ 2009, 180(8):841.
7. Bazelier M.T., de Vries F., Vestergaard P., Herings R.M., Gallagher A.M., Leufkens H.G., et al. Risk of fracture with thiazolidinediones: an individual patient data meta-analysis. Front Endocrinol 2013, 4:11.
8. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.
9. Higgins J.P.T., Altman D.G. Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions version 501 2008, Wiley, Chichester, UK. J.P.T. Higgins, S. Green (Eds.).
10. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
11. Bray G.A., Smith S.R., Banerji M.A., Tripathy D., Clement S.C., Buchanan T.A., et al. Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. Diabetes Obes Metab 2013, 15(10):931-937.
12. Bone H.G., Lindsay R., McClung M.R., Perez A.T., Raanan M.G., Spanheimer R.G. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2013, 98(12):4691-4701.
13. Bilezikian J.P., Josse R.G., Eastell R., Lewiecki E.M., Miller C.G., Wooddell M., et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013, 98(4):1519-1528.
14. Bach R.G., Brooks M.M., Lombardero M., Genuth S., Donner T.W., Garber A., et al. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 2013, 128(8):785-794.
15. Harrison S.A., Hamzeh F.M., Han J., Pandya P.K., Sheikh M.Y., Vierling J.M. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology 2012, 56(2):464-473.
16. Borges J.L., Bilezikian J.P., Jones-Leone A.R., Acusta A.P., Ambery P.D., Nino A.J., et al. A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80weeks of treatment in drug-naive type 2 diabetes mellitus patients. Diabetes Obes Metab 2011, 13(11):1036-1046.
17. Gruntmanis U., Fordan S., Ghayee H.K., Abdullah S.M., See R., Ayers C.R., et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcif Tissue Int 2010, 86(5):343-349.
18. Gold M., Alderton C., Zvartau-Hind M., Egginton S., Saunders A.M., Irizarry M., et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010, 30(2):131-146.
19. Home P.D., Pocock S.J., Beck-Nielsen H., Curtis P.S., Gomis R., Hanefeld M., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373(9681):2125-2135.
20. Tolman K.G., Freston J.W., Kupfer S., Alfonso P. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf 2009, 32(9):787-800.
21. Perez A., Zhao Z., Jacks R., Spanheimer R. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Curr Med Res Opin 2009, 25(12):2915-2923.
22. Kaku K., Daida H., Kashiwagi A., Yamashina A., Yamazaki T., Momomura S.I., et al. Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. Curr Med Res Opin 2009, 25(12):2925-2932.
23. Rosiglitazone and Plaque Study: a 12month randomised, double-blind, placebocontrolled, magnetic resonance imaging study to evaluate the effect of rosiglitazone on the structure and composition of carotid atherosclerotic plaques in subjects with type 2 diabetes mellitus and coexisting vascular disease or hypertension [study no 049653/351] 2008, GlaxoSmithKline, Brentford (UK), [Available: http://ctr.gsk.co.uk/Summary/rosiglitazone/studylist.asp (accessed 2008 Jul 13)].
24. A randomised, multi-centre, phase IV, double-blind, parallel group study comparing the effects of 52weeks' administration of AVANDAMET and metformin plus sulphonylurea on change in HbA1c from baseline in overweight type 2 diabetics poorly controlled on metformin [study no AVM100264] 2008, Glaxo-SmithKline, Brentford (UK), [Available: http://ctr.gsk.co.uk/Summary/rosiglitazone/studylist.asp (accessed 2008 Jul 13)].
25. RAS Rosiglitazone and Atherosclerosis Study: a 1year randomised, double-blind, parallel group, placebo controlled study to evaluate the efficacy of rosiglitazone on the progression of intima-media thickness in the carotid artery in subjects with insulin resistance syndrome and/or type 2 diabetes mellitus [study no 049653/334] 2008, GlaxoSmithKline, Brentford (UK), [Available: http://ctr.gsk.co.uk/Summary/rosiglitazone/studylist.asp (accessed 2008 Jul 13)].
26. Kahn S.E., Zinman B., Lachin J.M., Haffner S.M., Herman W.H., Holman R.R., et al. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008, 31(5):845-851.
27. Seufert J., Urquhart R. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. Diabetes Res Clin Pract 2008, 79(3):453-460.
28. Jain R., Osei K., Kupfer S., Perez A.T., Zhang J. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy 2006, 26(10):1388-1395.
29. Dormandy J.A., Charbonnel B., Eckland D.J.A., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366(9493):1279-1289.
30. Harslof T., Wamberg L., Moller L., Stodkilde-Jorgensen H., Ringgaard S., Pedersen S.B., et al. Rosiglitazone decreases bone mass and bone marrow fat. J Clin Endocrinol Metab 2011, 96(5):1541-1548.
31. Kanazawa I., Yamaguchi T., Yano S., Yamamoto M., Yamauchi M., Kurioka S., et al. Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. Osteoporos Int 2010, 21(12):2013-2018.
32. Berberoglu Z., Yazici A.C., Demirag N.G. Effects of rosiglitazone on bone mineral density and remodelling parameters in postmenopausal diabetic women: a 2-year follow-up study. Clin Endocrinol 2010, 73(3):305-312.
33. Glintborg D., Andersen M., Hagen C., Heickendorff L., Hermann A.P. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008, 93(5):1696-1701.
34. Grey A., Bolland M., Gamble G., Wattie D., Horne A., Davidson J., et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007, 92(4):1305-1310.
35. Meier C.K.M., Bodmer M., Jick S.S., Jick H., Meier C.R. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008, 168(8):5.
36. Dormuth C.R., Carney G., Carleton B., Bassett K., Wright J.M. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009, 169(15):1395-1402.
37. Habib Z.A., Havstad S.L., Wells K., Divine G., Pladevall M., Williams L.K. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010, 95(2):592-600.
38. Douglas I.J., Evans S.J., Pocock S., Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 2009, 6(9):e1000154.
39. Aubert R.E., Herrera V., Chen W., Haffner S.M., Pendergrass M. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab 2010, 12(8):716-721.
40. Betteridge D.J. Thiazolidinediones and fracture risk in patients with Type 2 diabetes. Diabet Med 2011, 28(7):759-771.
41. Grey A. Thiazolidinedione-induced skeletal fragility-mechanisms and implications. Diabetes Obes Metab 2009, 11(4):275-284.